|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KCNC2 |
Gene summary for KCNC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KCNC2 | Gene ID | 3747 |
| Gene name | potassium voltage-gated channel subfamily C member 2 | |
| Gene Alias | KV3.2 | |
| Cytomap | 12q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | Q96PR1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3747 | KCNC2 | GSM4909308 | Human | Breast | IDC | 3.17e-03 | 2.18e-01 | 0.158 |
| 3747 | KCNC2 | M1 | Human | Breast | IDC | 2.63e-31 | 8.84e-01 | 0.1577 |
| 3747 | KCNC2 | NCCBC2 | Human | Breast | DCIS | 1.14e-06 | 7.90e-01 | 0.1554 |
| 3747 | KCNC2 | GSM5252128_BPH327PrGF_Via | Human | Prostate | BPH | 2.41e-07 | 2.67e-01 | -0.1688 |
| 3747 | KCNC2 | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 1.67e-09 | 2.23e-01 | -0.1972 |
| 3747 | KCNC2 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 6.49e-10 | 2.70e-01 | -0.2126 |
| 3747 | KCNC2 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 1.36e-11 | 5.73e-01 | -0.2247 |
| 3747 | KCNC2 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 6.76e-12 | 3.10e-01 | -0.1433 |
| 3747 | KCNC2 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 2.48e-20 | 5.24e-01 | -0.23 |
| 3747 | KCNC2 | 048752_1579-all-cells | Human | Prostate | BPH | 9.23e-38 | 7.34e-01 | 0.1008 |
| 3747 | KCNC2 | 052095_1628-all-cells | Human | Prostate | BPH | 3.88e-38 | 8.15e-01 | 0.1032 |
| 3747 | KCNC2 | 052097_1595-all-cells | Human | Prostate | BPH | 6.06e-20 | 4.91e-01 | 0.0972 |
| 3747 | KCNC2 | 052099_1652-all-cells | Human | Prostate | BPH | 1.48e-48 | 1.01e+00 | 0.1038 |
| 3747 | KCNC2 | Dong_P1 | Human | Prostate | Tumor | 1.03e-06 | 1.51e-01 | 0.035 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001003814 | Breast | IDC | response to metal ion | 65/1434 | 373/18723 | 2.95e-10 | 3.42e-08 | 65 |
| GO:004885713 | Breast | IDC | neural nucleus development | 21/1434 | 64/18723 | 5.35e-09 | 4.28e-07 | 21 |
| GO:000963613 | Breast | IDC | response to toxic substance | 44/1434 | 262/18723 | 6.33e-07 | 3.00e-05 | 44 |
| GO:000931412 | Breast | IDC | response to radiation | 62/1434 | 456/18723 | 6.91e-06 | 2.10e-04 | 62 |
| GO:009723713 | Breast | IDC | cellular response to toxic substance | 24/1434 | 124/18723 | 2.05e-05 | 4.97e-04 | 24 |
| GO:001095913 | Breast | IDC | regulation of metal ion transport | 52/1434 | 406/18723 | 1.76e-04 | 2.97e-03 | 52 |
| GO:009730514 | Breast | IDC | response to alcohol | 36/1434 | 253/18723 | 2.29e-04 | 3.64e-03 | 36 |
| GO:003241111 | Breast | IDC | positive regulation of transporter activity | 20/1434 | 120/18723 | 7.64e-04 | 9.27e-03 | 20 |
| GO:00140751 | Breast | IDC | response to amine | 11/1434 | 49/18723 | 9.88e-04 | 1.11e-02 | 11 |
| GO:00432703 | Breast | IDC | positive regulation of ion transport | 36/1434 | 275/18723 | 1.11e-03 | 1.22e-02 | 36 |
| GO:002289812 | Breast | IDC | regulation of transmembrane transporter activity | 36/1434 | 278/18723 | 1.35e-03 | 1.40e-02 | 36 |
| GO:003241411 | Breast | IDC | positive regulation of ion transmembrane transporter activity | 18/1434 | 109/18723 | 1.53e-03 | 1.53e-02 | 18 |
| GO:00454713 | Breast | IDC | response to ethanol | 21/1434 | 137/18723 | 1.72e-03 | 1.67e-02 | 21 |
| GO:003476711 | Breast | IDC | positive regulation of ion transmembrane transport | 24/1434 | 167/18723 | 2.07e-03 | 1.95e-02 | 24 |
| GO:199008912 | Breast | IDC | response to nerve growth factor | 11/1434 | 56/18723 | 3.08e-03 | 2.61e-02 | 11 |
| GO:00423912 | Breast | IDC | regulation of membrane potential | 49/1434 | 434/18723 | 4.04e-03 | 3.25e-02 | 49 |
| GO:007124113 | Breast | IDC | cellular response to inorganic substance | 29/1434 | 226/18723 | 4.28e-03 | 3.34e-02 | 29 |
| GO:00324125 | Breast | IDC | regulation of ion transmembrane transporter activity | 33/1434 | 267/18723 | 4.38e-03 | 3.40e-02 | 33 |
| GO:00324096 | Breast | IDC | regulation of transporter activity | 37/1434 | 310/18723 | 4.77e-03 | 3.66e-02 | 37 |
| GO:00347644 | Breast | IDC | positive regulation of transmembrane transport | 28/1434 | 219/18723 | 5.19e-03 | 3.86e-02 | 28 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KCNC2 | SNV | Missense_Mutation | c.1762G>A | p.Asp588Asn | p.D588N | Q96PR1 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.889) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | |
| KCNC2 | SNV | Missense_Mutation | c.1760N>T | p.Ser587Phe | p.S587F | Q96PR1 | protein_coding | deleterious_low_confidence(0.02) | benign(0.212) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| KCNC2 | SNV | Missense_Mutation | c.1382G>A | p.Gly461Glu | p.G461E | Q96PR1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| KCNC2 | SNV | Missense_Mutation | c.857A>T | p.Glu286Val | p.E286V | Q96PR1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| KCNC2 | insertion | Nonsense_Mutation | novel | c.786_787insTGCAAATTCTTCTAATATATATCTAACAACTGTT | p.Pro263CysfsTer5 | p.P263Cfs*5 | Q96PR1 | protein_coding | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| KCNC2 | SNV | Missense_Mutation | novel | c.800N>A | p.Gly267Asp | p.G267D | Q96PR1 | protein_coding | tolerated(0.33) | benign(0.005) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KCNC2 | SNV | Missense_Mutation | rs773079241 | c.517G>A | p.Asp173Asn | p.D173N | Q96PR1 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| KCNC2 | insertion | Frame_Shift_Ins | novel | c.158_159insA | p.Leu54AlafsTer199 | p.L54Afs*199 | Q96PR1 | protein_coding | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| KCNC2 | SNV | Missense_Mutation | c.245N>T | p.Ala82Val | p.A82V | Q96PR1 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.992) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| KCNC2 | SNV | Missense_Mutation | rs199735865 | c.1684N>T | p.Arg562Cys | p.R562C | Q96PR1 | protein_coding | tolerated_low_confidence(0.09) | benign(0.014) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3747 | KCNC2 | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL1200728 | GUANIDINE HYDROCHLORIDE | |
| 3747 | KCNC2 | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL113461 | TEDISAMIL | |
| 3747 | KCNC2 | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL2107762 | NERISPIRDINE | |
| 3747 | KCNC2 | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL284348 | DALFAMPRIDINE | |
| 3747 | KCNC2 | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | 135652463 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |